Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in brain excitatory neurons (121 nCPM) | 1.00 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 15386
Sealed predictions
- CBLN2 in dopamine neurons, braak+0.55 (p 0.125) → +0.47 (p 0.197)receipt 15394
Swarm cases
receipt 15394: CBLN2 in dopamine neurons, braak
- power
- full sample +0.46 (p 0.055, n 18), 95% CI -0.01 to +0.76. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.47 (p 0.049, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.40 (p 0.099, n 18). could be the mix.
- skeptic
- leave-one-out range +0.38 to +0.61, sign flips 0; without severely affected donors +0.46 (p 0.055, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CBLN2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts